TSC2 and cancer: Our analysis of tumour mutation frequency of different ferroptosis phenotypes suggested that a high mutation frequency in TP53, ARID1A, TSC2 and FAT3 in the Ferroptosis‐H phenotype might worsen the prognosis of patients with HCC by suppressing the ferroptosis process as well as the loss of tumour‐suppressive function in cancer.